Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)

Posted Dec 06 2010 9:02pm
The etiology and pathogenesis of the scleroderma disorders are poorly understood. As a result, treatment of these conditions is difficult, incomplete, and not curative. (See "Risk factors for and possible causes of systemic sclerosis (scleroderma)" and "Pathogenesis of systemic sclerosis (scleroderma)".)

Patients with diffuse as opposed to limited cutaneous involvement are the most likely to have early and sometimes severe internal organ involvement. These patient are classified as having diffuse cutaneous systemic sclerosis (dcSSc). This is the subset of patients for whom systemic approaches to treatment are most often used.

This topic reviews the systemic approaches to the treatment of systemic sclerosis (SSc). An overview of the treatment of scleroderma disorders and a discussion of the clinical manifestations and diagnosis of SSc are presented separately. (See "Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults" and "Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults" and "Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults".)


Post a comment
Write a comment: